Hu Qing, Luo Zhou, Xu Tao, Zhang Jun-Ying, Zhu Ying, Chen Wei-Xian, Zhong Shan-Liang, Zhao Jian-Hua, Tang Jin-Hai
Department of General Surgery, Xuzhou Medical College, Xuzhou, China E-mail :
Asian Pac J Cancer Prev. 2014;15(1):11-6. doi: 10.7314/apjcp.2014.15.1.11.
Accurate diagnosis and proper monitoring of cancer patients remain important obstacles for successful cancer treatment. The search for cancer biomarkers can aid in more accurate prediction of clinical outcome and may also reveal novel predictive factors and therapeutic targets. One such prognostic marker seems to be FOXA1. Many studies have shown that FOXA1 is strongly expressed in a vast majority of cancers, including breast cancer, in which high expression is associated with a good prognosis. In this review, we summarize the role of this transcription factor in the development and prognosis of breast cancer in the hope of providing insights into utility of FOXA1 as a novel biomarker.
对癌症患者进行准确诊断和适当监测仍然是癌症成功治疗的重要障碍。寻找癌症生物标志物有助于更准确地预测临床结果,还可能揭示新的预测因素和治疗靶点。FOXA1似乎就是这样一种预后标志物。许多研究表明,FOXA1在绝大多数癌症中都有强烈表达,包括乳腺癌,其中高表达与良好预后相关。在本综述中,我们总结了这种转录因子在乳腺癌发生发展和预后中的作用,希望能为FOXA1作为一种新型生物标志物的应用提供见解。